Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
Abstract:589 Background: Endocrine therapy (ET) is the therapeutic mainstay for ER+ BC. Giredestrant is a highly potent, nonsteroidal, oral, selective ER antagonist and degrader (SERD) which has demonstrated robust ER occupancy, is well tolerated, and has previously shown encouraging antitumor activity as monotherapy and in combination with P in metastatic BC. coopERA BC (NCT04436744) evaluated giredestrant in eBC and met its primary endpoint, highlighting superior Ki67 suppression with single-agent giredestrant vs A … Show more
“…acelERA is a randomized phase II trial of giredestrant vs fulvestrant or aromatase inhibitor that failed to meet its primary endpoint of superior PFS for the study drug [79], although subgroup analysis of patients with baseline ESR1 mutations appeared to show promising effects. Giredestrant did outperform anastrozole in reducing Ki67 expression and inducing complete cell cycle arrest when used as neoadjuvant therapy for previously untreated patients from the coopERA study in postmenopausal women with hormone receptor-positive, HER2 − early breast cancer [80]. Giredestrant is currently explored as first-line therapy for advanced breast cancer and early-stage breast cancer.…”
Section: Discussionmentioning
confidence: 99%
“…For tumors that are hormonal therapy naïve or first-line therapy, oral SERDs plus CDK4/6 inhibitors are being compared with AIs plus CDK4/6 inhibitors as in AMEERA-5 [87] (amcenestrant), SERENA 4 [88](camizestrant), or with physicians' choice plus CDK4/6 inhibitors as in acelERA Breast Cancer [78] (giredestrant) and in tumors with ESR1 mutation, as in SERENA 6 [89] (camizestrant). In the neoadjuvant setting, oral SERDs are being explored in locally advanced HR + /HER2 − stage III breast cancer against AIs alone as in AMEERA-4 [90] (amcenestrant) or in combination with CDK4/6 inhibitors as in coopERA BC study [80] (giredestrant). Similarly, in the adjuvant treatment of early breast cancer, oral SERDs are being studied against AIs or physicians' choice as in the Lidera Breast Cancer Study [91] (giredestrant) or tamoxifen as in AMEERA-6 [92] (amcenestrant) in HR + /HER2 − stages I-II early breast cancers.…”
Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER +) breast cancer. ER can be activated in a ligand-dependent and independent manner. Currently available ER-targeting agents include selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs). Estrogen receptor mutation (ESR1 mutation) is one of the common mechanisms by which breast cancer becomes resistant to additional therapies from SERMs or AIs. These tumors remain sensitive to SERDs such as fulvestrant. Fulvestrant is limited in clinical utilization by its intramuscular formulation and once-monthly injection in large volumes. Oral SERDs are being rapidly developed to replace fulvestrant with the potential of higher efficacy and lower toxicities. Elacestrant is the first oral SERD that went through a randomized phase III trial showing increased efficacy, especially in tumors bearing ESR1 mutation, and good tolerability. Two other oral SERDs recently failed to achieve the primary endpoints of longer progression-free survival (PFS). They targeted tumors previously treated with several lines of prior therapies untested for ESR1 mutation. Initial clinical trial data demonstrated that tumors without the ESR1 mutation are less likely to benefit from the SERDs and may still respond to SERMs or AIs, including tumors previously exposed to hormonal therapy. Testing for ESR1 mutation in ongoing clinical trials and in hormonal therapy for breast cancer is highly recommended. Novel protein degradation technologies such as proteolysis-targeting chimera (PROTACS), molecular glue degrader (MGD), and lysosome-targeting chimeras (LYTACS) may result in more efficient ER degradation, while ribonuclease-targeting chimeras (RIBOTAC) and small interfering RNA (siRNA) may inhibit the production of ER protein.
“…acelERA is a randomized phase II trial of giredestrant vs fulvestrant or aromatase inhibitor that failed to meet its primary endpoint of superior PFS for the study drug [79], although subgroup analysis of patients with baseline ESR1 mutations appeared to show promising effects. Giredestrant did outperform anastrozole in reducing Ki67 expression and inducing complete cell cycle arrest when used as neoadjuvant therapy for previously untreated patients from the coopERA study in postmenopausal women with hormone receptor-positive, HER2 − early breast cancer [80]. Giredestrant is currently explored as first-line therapy for advanced breast cancer and early-stage breast cancer.…”
Section: Discussionmentioning
confidence: 99%
“…For tumors that are hormonal therapy naïve or first-line therapy, oral SERDs plus CDK4/6 inhibitors are being compared with AIs plus CDK4/6 inhibitors as in AMEERA-5 [87] (amcenestrant), SERENA 4 [88](camizestrant), or with physicians' choice plus CDK4/6 inhibitors as in acelERA Breast Cancer [78] (giredestrant) and in tumors with ESR1 mutation, as in SERENA 6 [89] (camizestrant). In the neoadjuvant setting, oral SERDs are being explored in locally advanced HR + /HER2 − stage III breast cancer against AIs alone as in AMEERA-4 [90] (amcenestrant) or in combination with CDK4/6 inhibitors as in coopERA BC study [80] (giredestrant). Similarly, in the adjuvant treatment of early breast cancer, oral SERDs are being studied against AIs or physicians' choice as in the Lidera Breast Cancer Study [91] (giredestrant) or tamoxifen as in AMEERA-6 [92] (amcenestrant) in HR + /HER2 − stages I-II early breast cancers.…”
Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER +) breast cancer. ER can be activated in a ligand-dependent and independent manner. Currently available ER-targeting agents include selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs). Estrogen receptor mutation (ESR1 mutation) is one of the common mechanisms by which breast cancer becomes resistant to additional therapies from SERMs or AIs. These tumors remain sensitive to SERDs such as fulvestrant. Fulvestrant is limited in clinical utilization by its intramuscular formulation and once-monthly injection in large volumes. Oral SERDs are being rapidly developed to replace fulvestrant with the potential of higher efficacy and lower toxicities. Elacestrant is the first oral SERD that went through a randomized phase III trial showing increased efficacy, especially in tumors bearing ESR1 mutation, and good tolerability. Two other oral SERDs recently failed to achieve the primary endpoints of longer progression-free survival (PFS). They targeted tumors previously treated with several lines of prior therapies untested for ESR1 mutation. Initial clinical trial data demonstrated that tumors without the ESR1 mutation are less likely to benefit from the SERDs and may still respond to SERMs or AIs, including tumors previously exposed to hormonal therapy. Testing for ESR1 mutation in ongoing clinical trials and in hormonal therapy for breast cancer is highly recommended. Novel protein degradation technologies such as proteolysis-targeting chimera (PROTACS), molecular glue degrader (MGD), and lysosome-targeting chimeras (LYTACS) may result in more efficient ER degradation, while ribonuclease-targeting chimeras (RIBOTAC) and small interfering RNA (siRNA) may inhibit the production of ER protein.
“…The coopERA trial is a randomized, phase II neoadjuvant trial of giredestrant versus anastrozole, with the addition of palbociclib in both arms after 14 days of treatment. The final analysis on 201 evaluable patients on the lead-in phase of the study (without palbociclib) has shown a statistically significant reduction in Ki67 after 14 days of treatment with giredestrant compared to AI (relative reduction in geometric Ki67 of − 75% vs − 67%, respectively) [75]. However, giredestrant combined with palbociclib did not show an improvement in terms of pCR rate compared to the control arm.…”
Section: Serds With Basic Amino Side Chainsmentioning
“… 76 At the end of the neoadjuvant combination treatment phase, geometric mean relative reduction in Ki67 was again superior in the giredestrant arm at −81% compared with −74%, but there was no difference in the ORR nor pathological complete response rate between the trial arms. 77 …”
Section: Oral Serd Window Trialsmentioning
confidence: 99%
“…76 At the end of the neoadjuvant combination treatment phase, geometric mean relative reduction in Ki67 was again superior in the giredestrant arm at −81% compared with −74%, but there was no difference in the ORR nor pathological complete response rate between the trial arms. 77 In the AMEERA-4 trial, 105 patients with ER positive, HER2 negative early breast cancer with a primary tumor ≥ 1.0 cm and Ki67 ≥ 15% were randomized 1:1:1 to amcenestrant 400 mg daily, amcenestrant 200 mg daily, or letrozole 2.5 mg daily for 2 weeks before surgery. 78 No formal statistical comparisons were performed as the study had closed early due to slow trial enrollment.…”
Several endocrine therapies are currently available for the treatment of estrogen receptor (ER) positive breast cancer, but the clinical benefit of these agents is limited by endocrine therapy drug resistance. A common mechanism of endocrine therapy resistance is
ESR1
mutations. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has activity against
ESR1
mutant tumors but requires intramuscular injection and has poor bioavailability that precludes optimal drug dosing. This led to the development of second-generation SERDs which are potent and have improved oral bioavailability and pharmacokinetics. Several of these oral SERDs are now in phase III trials in both the early and advanced ER positive breast cancer settings. This review summarizes the background of oral SERD development, the current status and future perspectives.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.